Large cell neuroendocrine carcinoma of the lung controlled for 4 years by a single administration of pembrolizumab: A case report

Large cell neuroendocrine carcinoma of the lung controlled for 4 years by a single administration of pembrolizumab: A case report

Abstract Large cell neuroendocrine carcinoma of the lung (LCNEC) is a rare and highly progressive tumor with a poor prognosis. Although immune checkpoint inhibitors have been approved for treatment of both small cell and non–small cell lung cancers, their role in the treatment of LCNEC is unclear. W...

Full description

Bibliographic Details
Main Authors: Masayuki Watanabe, Yuki Matsumura, Hikaru Yamaguchi, Hayato Mine, Hironori Takagi, Yuki Ozaki, Mitsuro Fukuhara, Satoshi Muto, Naoyuki Okabe, Yutaka Shio, Hiroyuki Suzuki
Format: Article
Language:English
Published: Wiley 2022-10-01
Series:Thoracic Cancer
Subjects:
immune checkpoint inhibitor
immune‐related adverse event
large cell neuroendocrine carcinoma of the lung
Online Access:https://doi.org/10.1111/1759-7714.14615

Internet

https://doi.org/10.1111/1759-7714.14615

Similar Items